Pivekimab is a novel human IgG1 monoclonal antibody designed for targeted immunotherapy, which uniquely and simultaneously binds to both interleukin-3 (IL-3) and its receptor subunit CD123. This dual-targeting mechanism is intended to disrupt the IL-3 signaling pathway by sequestering the cytokine and blocking its interaction with the receptor on the cell surface. Developed primarily for the treatment of certain hematologic malignancies, pivekimab aims to inhibit the survival and proliferation of cancerous cells, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML) cells, that often overexpress CD123 and depend on IL-3 for growth and survival.